vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial

GuruFocus.com
昨天

vTv Therapeutics (VTVT, Financials) surged 42.99% to $21.23 on Monday after the U.S. Food and Drug Administration lifted a clinical hold on the company's development program for cadisegliatin, an experimental oral therapy for type 1 diabetes.

  • Warning! GuruFocus has detected 4 Warning Signs with VTVT.

Following an adjustment to cut its length from 12 months to six months, the business intends to start its Phase 3 CATT1 study. According to a statement by vTv Therapeutics, the updated schedule seeks to hasten the gathering of topline data and speed future regulatory filings.Designed as an oral supplement to insulin treatment, cadisegliatin is a glucokinase activator specific for the liver. The business claims that the medicine has been generally well tolerated after testing over 500 people for up to six months.Following a chromatographic signal in a metabolism study not able to be resolved with conventional mass spectrometry, the FDA has put a clinical halt on the experiment in July 2024. At the time, no patients had been registered for the experiment; earlier research had not shown any appreciable safety issues. Following vTv's entire response to the FDA, which indicated the signal was an experimental artifact, the clinical hold was released March 14.The main endpoint, which gauges degrees of moderate to severe hypoglycemia at six months, will not change with the adjustment to the research protocol. The revised scheme eliminates an extra six-month safety monitoring period, however.Late-stage biopharmaceutical business vTv Therapeutics is studying cadisegliatin as a first-in-class type 1 diabetes treatment.

The business has not said when it hopes to release topline findings from the CATT1 study.

This article first appeared on GuruFocus.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10